(PYXS)

NMS – Real Time Price. Currency in USD

1.31

-0.08 (-5.76%)

At close: Mar 27, 2026, 4:00 PM EDT

1.29

-0.02 (-1.53%)

After-hours: Mar 27, 2026, 7:51 PM EDT

About the company

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Key Executives

Name	Position
Donna Regalado	Head of Human Resources
Dr. Balu N. Balasubramanian Ph.D.	Interim Chief Technology Officer
Dr. Charles T. Gombar Ph.D.	Senior Vice President of Portfolio & Program Management
Dr. Jan Pinkas Ph.D.	Chief Scientific Officer
Dr. Michael Bui	Head of Global Regulatory Affairs
Dr. Supriya Roth Ph.D.	Head of Commercial Development
Mr. Alex Kane M.B.A.	Senior Vice President of Investor Relations & Capital Markets